Skip to main content
SpringerLink
Log in

Chronic Lymphocytic Leukemia: Who, How, and Where?

  • Chapter
  • First Online:
Book cover Chronic Lymphocytic Leukemia

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Chronic lymphocytic leukemia (CLL) is an extremely fascinating and enigmatic disease where a distinctive homogenous immunophenotype comes along with a remarkable biological and clinical heterogeneity. Key mechanisms underlying CLL onset and progression have been recently dissected. Recent progresses led to the identification of a preneoplastic condition of the disease (i.e., monoclonal B-cell lymphocytosis, MBL) that shed light on very early events responsible for CLL development but also on factors defining the thin red line between clinically overt disease and preclinical condition. The introduction of high-throughput sequencing techniques has increased our knowledge on the complexity of the genomic landscape of CLL cells and introduced the concept of clonal architecture and evolution, proving that both are influenced by any therapeutic intervention and this should be taken into account when selecting time and type of treatment in CLL patients. We gained further knowledge on the role of B-cell receptor (BcR) signaling and accumulated several hints supporting its key role in CLL development and progression. This led, for the first time in CLL history, to a targeted treatment approach, with novel inhibitors now available in the clinical practice for our CLL patients. That notwithstanding, there are many open questions in CLL pathogenesis that need to be addressed, with the next years hopefully leading us to shed light on the complex intertwining between relevant gene mutations and microenvironmental interactions to finally elucidate the pathogenetic mechanisms responsible of the onset of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–15.

    Article  CAS  PubMed  Google Scholar 

  2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26:4497–503.

    Article  CAS  PubMed  Google Scholar 

  4. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27:1–10.

    Article  CAS  PubMed  Google Scholar 

  5. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126:2265–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Slager SL, Caporaso NE, de Sanjose S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol. 2013;50:296–302.

    Article  CAS  PubMed  Google Scholar 

  7. Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica. 2009;94:647–53.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40:1204–10.

    Article  CAS  PubMed  Google Scholar 

  9. Slager SL, Rabe KG, Achenbach SJ, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117:1911–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet. 2010;42:132–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45:868–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Speedy HE, Di Bernardo MC, Sava GP, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2014;46:56–60.

    Article  CAS  PubMed  Google Scholar 

  13. Berndt SI, Camp NJ, Skibola CF, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016;7:10933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood. 2013;122:2848–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Liu P, Xu B, Shen W, et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012;26:1293–300.

    Article  CAS  PubMed  Google Scholar 

  16. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325–32.

    Article  PubMed  Google Scholar 

  17. Campo E, Ghia P, Montserrat E, Harris NL, Muller-Hermelink HK, Stein H, Swerdlow SH. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, International Agency for Research on Cancer & World Health Organization, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.

    Google Scholar 

  18. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24:512–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359:575–83.

    Article  CAS  PubMed  Google Scholar 

  20. Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009;27:3959–63.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood. 2009;114:26–32.

    Article  CAS  PubMed  Google Scholar 

  22. Fazi C, Scarfo L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118:6618–25.

    Article  CAS  PubMed  Google Scholar 

  23. Vardi A, Dagklis A, Scarfo L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013;121:4521–8.

    Article  CAS  PubMed  Google Scholar 

  24. Klinger M, Zheng J, Elenitoba-Johnson KS, Perkins SL, Faham M, Bahler DW. Next-generation IgVH sequencing CLL-like monoclonal B-cell lymphocytosis reveals frequent oligoclonality and ongoing hypermutation. Leukemia. 2016;30:1055–61.

    Article  CAS  PubMed  Google Scholar 

  25. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136–41.

    Article  CAS  PubMed  Google Scholar 

  26. Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia. 2016;30:331–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20:246–59.

    Article  CAS  PubMed  Google Scholar 

  28. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088–101.

    Article  CAS  PubMed  Google Scholar 

  29. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209:2183–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med. 1982;155:623–8.

    Article  CAS  PubMed  Google Scholar 

  33. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50.

    Article  CAS  PubMed  Google Scholar 

  34. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32.

    Article  CAS  PubMed  Google Scholar 

  35. Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1278–9.

    Article  CAS  PubMed  Google Scholar 

  36. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

    Article  CAS  PubMed  Google Scholar 

  39. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507–16.

    Article  CAS  PubMed  Google Scholar 

  42. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    Article  CAS  PubMed  Google Scholar 

  43. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40.

    Article  CAS  PubMed  Google Scholar 

  46. Strati P, Abruzzo LV, Wierda WG, O’Brien S, Ferrajoli A, Keating MJ. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:420–7.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012;97:437–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26–9.

    Article  CAS  PubMed  Google Scholar 

  49. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119:2854–62.

    Article  CAS  PubMed  Google Scholar 

  50. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–9.

    Article  PubMed  Google Scholar 

  51. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589–97.

    Article  CAS  PubMed  Google Scholar 

  52. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114:5307–14.

    Article  CAS  PubMed  Google Scholar 

  53. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29:877–85.

    Article  CAS  PubMed  Google Scholar 

  54. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365:2497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44:47–52.

    Article  CAS  PubMed  Google Scholar 

  57. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121:260–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Golas MM, Sander B, Will CL, Luhrmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science. 2003;300:980–4.

    Article  CAS  PubMed  Google Scholar 

  61. Ramsay AJ, Rodriguez D, Villamor N, et al. Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia. 2013;27:1600–3.

    Article  CAS  PubMed  Google Scholar 

  62. Riches JC, O’Donovan CJ, Kingdon SJ, et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014;123:4101–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119:521–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Arruga F, Gizdic B, Serra S, et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia. 2014;28:1060–70.

    Article  CAS  PubMed  Google Scholar 

  65. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856–65.

    Article  CAS  PubMed  Google Scholar 

  66. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208:1389–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Mansouri L, Sutton LA, Ljungstrom V, et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212:833–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Baliakas P, Hadzidimitriou A, Agathangelidis A, et al. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood. 2015;126:1043–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Rossi D. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology Am Soc Hematol Educ Program. 2014;2014:113–8.

    Article  PubMed  Google Scholar 

  70. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120:4191–6.

    Article  CAS  PubMed  Google Scholar 

  72. Lazarian G, Guieze R, Wu CJ. Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:984–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123:2139–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29:895–900.

    Article  CAS  PubMed  Google Scholar 

  76. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Jones D, Woyach JA, Zhao W, et al. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. Leukemia. 2017;31:1645–7.

    Article  CAS  PubMed  Google Scholar 

  78. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073–83.

    Article  CAS  PubMed  Google Scholar 

  79. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235–46.

    CAS  PubMed  Google Scholar 

  80. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288–94.

    Article  CAS  PubMed  Google Scholar 

  81. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.

    CAS  PubMed  Google Scholar 

  82. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.

    CAS  PubMed  Google Scholar 

  83. Vardi A, Agathangelidis A, Sutton LA, Ghia P, Rosenquist R, Stamatopoulos K. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res. 2014;74:4211–6.

    Article  CAS  PubMed  Google Scholar 

  84. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest. 2004;113:1008–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105:1678–85.

    Article  CAS  PubMed  Google Scholar 

  86. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879–85.

    Article  CAS  PubMed  Google Scholar 

  87. Stamatopoulos K, Agathangelidis A, Rosenquist R, Ghia P. Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia. 2017;31:282–91.

    Article  CAS  PubMed  Google Scholar 

  88. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259–70.

    Article  CAS  PubMed  Google Scholar 

  89. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119:4467–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med. 2013;19:115–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Ntoufa S, Papakonstantinou N, Apollonio B, et al. B cell anergy modulated by TLR1/2 and the miR-17 approximately 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol. 2016;196:4410–7.

    Article  CAS  PubMed  Google Scholar 

  93. Del Giudice I, Chiaretti S, Santangelo S, et al. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients’ prognosis. Am J Hematol. 2014;89:74–82.

    Article  CAS  PubMed  Google Scholar 

  94. Gounari M, Ntoufa S, Apollonio B, et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood. 2015;125:3580–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101:959–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121:4902–5.

    Article  CAS  PubMed  Google Scholar 

  97. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013;27:2196–9.

    Article  CAS  PubMed  Google Scholar 

  98. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1:e74–84.

    Article  PubMed  Google Scholar 

  99. Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013;210:59–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111:3838–48.

    Article  CAS  PubMed  Google Scholar 

  101. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008;14:665–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115:3907–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112:188–95.

    Article  CAS  PubMed  Google Scholar 

  104. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087–93.

    Article  CAS  PubMed  Google Scholar 

  105. Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309–12.

    Article  CAS  PubMed  Google Scholar 

  106. Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P, Degano M. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:15746. https://doi.org/10.1038/ncomms15746.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Purroy N, Abrisqueta P, Carabia J, et al. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015;6:7632–43.

    Article  PubMed  Google Scholar 

  109. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist’s view of lymph node microenvironment. Semin Diagn Pathol. 2011;28:161–6.

    Article  PubMed  Google Scholar 

  110. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655–63.

    CAS  PubMed  Google Scholar 

  111. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030–7.

    Article  CAS  PubMed  Google Scholar 

  112. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113:3050–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011;117:1662–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106:1012–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Filip AA, Cisel B, Koczkodaj D, Wasik-Szczepanek E, Piersiak T, Dmoszynska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis. 2013;50:263–70.

    Article  CAS  PubMed  Google Scholar 

  116. Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007;110:4012–21.

    Article  CAS  PubMed  Google Scholar 

  117. Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123:1709–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002;32:1403–13.

    Article  CAS  PubMed  Google Scholar 

  119. Scielzo C, Apollonio B, Scarfo L, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:1760–7.

    Article  CAS  PubMed  Google Scholar 

  120. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120:1412–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  122. Lutzny G, Kocher T, Schmidt-Supprian M, et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell. 2013;23:77–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Maffei R, Bulgarelli J, Fiorcari S, et al. Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One. 2014;9:e98818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Heinig K, Gatjen M, Grau M, et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov. 2014;4:1448–65.

    Article  CAS  PubMed  Google Scholar 

  125. Cols M, Barra CM, He B, et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012;188:6071–83.

    Article  CAS  PubMed  Google Scholar 

  126. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117:5463–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Herndon TM, Chen SS, Saba NS, et al. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017;31:1340–7.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17:1374–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009;114:4832–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Vardi A, Vlachonikola E, Karypidou M, et al. Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. Leukemia. 2017;31:1555–61.

    Article  CAS  PubMed  Google Scholar 

  132. te Raa GD, Pascutti MF, Garcia-Vallejo JJ, et al. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014;123:717–24.

    Article  CAS  Google Scholar 

  133. Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Choi MY, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016;29:40–53.

    Article  PubMed  Google Scholar 

  135. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94:3658–67.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Strategic Research Program on CLL and B-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy

    Lydia Scarfò & Paolo Ghia

Authors
  1. Lydia Scarfò
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Ghia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Ghia .

Editor information

Editors and Affiliations

  1. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Michael Hallek

  2. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Barbara Eichhorst

  3. Division of Molecular Pathology, The Institute of Cancer Research, London, UK

    Daniel Catovsky

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Scarfò, L., Ghia, P. (2019). Chronic Lymphocytic Leukemia: Who, How, and Where?. In: Hallek, M., Eichhorst, B., Catovsky, D. (eds) Chronic Lymphocytic Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-11392-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11392-6_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11391-9

  • Online ISBN: 978-3-030-11392-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation